Pear Therapeutics
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics
December 11, 2018Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …
Novartis expands Pear partnership to tackle opioid and substance use disorder
April 23, 2018Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder
Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …
Novartis forms a Pear to develop mobile therapies
March 2, 2018Medical Communications, Research and Development Novartis, Pear Therapeutics, biotech, drugs, pharma, pharmaceutical
Novartis has announced an agreement between Pear Therapeutics and itself to develop two digital therapeutics, one in schizophrenia and one …
FDA approves first medical app, for use in addiction
September 18, 2017Sales and Marketing Pear Therapeutics, biotech, drugs, pharma, pharmaceutical, reset
The FDA has taken a major step in the digitisation of healthcare by handing out the first medical app approval: …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
